+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Age: 18Years - 80Years
All Genders
ID05271214

Careful Medical Management for Adults with Advanced Heart Failure Considering Left Ventricular Assist Device LVAD Implantation

Led by Tel-Aviv Sourasky Medical Center · Updated on 2022-03-08

100

Participants Needed

1

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

This research focuses on patients with advanced heart failure who are candidates for a left ventricular assist device LVAD implantation. These patients have severe left ventricular systolic dysfunction with an ejection fraction below 30% and severe heart failure symptoms classified as New York Heart Association Class III-IV. The study aims to carefully evaluate and manage these patients to possibly avoid or delay the need for LVAD implantation by optimizing medical therapy and other interventions. Participants undergo thorough cardiac assessments including echocardiography, right heart catheterization, and cardiopulmonary exercise tests. Initial treatment includes intravenous medications like milrinone and furosemide, vitamin and iron supplementation, and guideline-directed therapies such as beta blockers, hydralazine, nitrates, digoxin, and renin-angiotensin-aldosterone system inhibitors. Coronary interventions and cardiac resynchronization therapy are applied when appropriate. After hospital discharge, patients receive close follow-up at intervals of 3 to 14 days, including clinical evaluations, lab tests, and repeated cardiac imaging. Intravenous diuretics and inotropes may be administered as needed during follow-up. Throughout the study, participants undergo repeated evaluations using clinical assessments, laboratory tests, echocardiography, and cardiopulmonary exercise tests to monitor heart function and symptoms. Right heart catheterization may be repeated individually. The main outcome measured at 3 months is the New York Heart Association NYHA Class, with secondary outcomes including maximal oxygen consumption, natriuretic peptide levels, and left ventricular size at 3 to 6 months. The study continues through regular monitoring and therapeutic adjustments, aiming to improve or stabilize patients heart failure status without immediate LVAD implantation.

CONDITIONS

Brief Title

Conservative Management of Left Ventricular Assist Device Candidates

Research Team

O

Ofer Havakuk, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here